Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company
Cue Biopharma appointed Shao-Lee Lin, M.D., Ph.D., as Chief Executive Officer, President and Director, succeeding interim CEO Lucinda Warren. Dr. Lin brings over 25 years of experience, including founding ACELYRIN and leading it to an IPO, and held leadership roles at Horizon Therapeutics, AbbVie, and Amgen.
Key figures
- Drug Name
- CUE-401
- Phase Of Trial
- Phase 1
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.